Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe First Hospital of Jilin University
About this trial
Acute gastrointestinal injury (AGI) is a common but not fully understood organ dysfunction in critically ill patients. Current AGI grading systems rely primarily on clinical presentation and feeding tolerance, which are inherently subjective and may not accurately reflect the underlying biological severity of intestinal damage.
Intestinal fatty acid-binding protein (I-FABP) is a protein expressed almost exclusively in the cytoplasm of mature small intestinal epithelial cells. In cases of ischemia, inflammation, or mechanical injury, I-FABP is rapidly released into the bloodstream and subsequently excreted in the urine. These characteristics make I-FABP a highly specific biomarker for intestinal epithelial cell injury and intestinal ischemia.
A prospective study combining paired blood and urine I-FABP measurements, standardized AGI assessment, and careful consideration of surgical status was conducted to elucidate the role of intestinal epithelial cell injury in acute gastrointestinal dysfunction.
Eligibility criteria
Qualifiers
1、 Age ≥18 years.
2 、Admission to the ICU with an expected ICU stay ≥48 hours.
3 、Availability of paired plasma and urine samples within 24 hours of ICU admission.
4 、Feasible daily gastrointestinal function assessment to complete AGI grading (ESICM definition).
Disqualifiers
1、 Pre-existing inflammatory bowel disease.
2 、Short bowel syndrome.
3、 Chronic intestinal failure requiring long-term parenteral nutrition.
4、 Pregnancy.
Trial design
Treatments tested in this trial
- Plasma and urine I-FABP measurement
Treatment groups
500 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov